• Home
  • Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.

Author List
Rugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DA, Carter GC, Sheffield KM, Li L, Andre VAM, Li XI, Frenzel M, Huang YJ, Dickler MN, Tolaney SM
Publication
Breast cancer research and treatment
Publication ID (Profile URL)
https://researcherprofiles.org/profile/130281838
Publication Year
2020
PubMed ID
32789591
Publication Title
Rugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DA, Carter GC, Sheffield KM, Li L, Andre VAM, Li XI, Frenzel M, Huang YJ, Dickler MN, Tolaney SM. Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1. Breast Cancer Res Treat. 2020 Nov; 184(1):161-172.